📖
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz–Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study
Mireille Mpoudi-Etame, Tamara Tovar Sanchez, Marwân-Al-Qays Bousmah, Pierrette Omgba Bassega, Justin Olinga, Eric Mimbe, Michel Foalem, Camille Chiep, Serge Edimo, Marie Varloteaux, Raphaël Pelloquin, Nadine Lamare, Sylvie Boyer, Martine Peeters, Jacques Reynes, Alexandra Calmy, Andrew Hill, Eric Delaporte, Charles Kouanfack, Ahidjo Ayouba, A Agholeng, Christelle Butel, B Granouillac, A Lacroix, Sandrine Leroy, L Serrano, C Kounfack, Nicole Vidal, P Fouda, R Mougnoutou, V Omgba, S Tchokonte Ngandé, B Ymele, L Donfack, A Kambi, C Epoupa Mpacko, M Fotso, R Moukoko, T Nké, A Akamba, S Lekelem, S Ngono, S Tongo Fotack, M Tanga, M Tsafack, A Bissek, L Ciaffi, S Lem, M Niba, N Camille, Eitel Mpoudi-Ngole, E Ebong, G Edoul Mbesse, M Tongo, P Huynh, Gwenaëlle Maradan, Marie Libérée Nishimwe, Bruno Spire, Gilles Peytavin, Mp Lê, Yazdan Yazdanpanah, A Diallo, I Fournier, A Montoyo, N Mercier, Ventizlava Petrov‐sanchez, J Jean-Rassat, Claire Rekacewicz, C Perez Casas

Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz–Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study

Science & Mathematics Published 2023 Verification Pending

Overview & Synopsis

Background: A prospective study was extended to the new antiretroviral and monitoring strategies in HIV-infected adults in low-income countries (NAMSAL-ANRS)-12313 trial, a 96-week open-label, multicenter, randomized phase 3 trial comparing dolutegravir (DTG) 50 mg with efavirenz 400 mg (EFV400), both administered with tenofovir disoproxil fumarate and lamivudine (TDF/3TC) as first-line treatment for antiretroviral therapy (ART)–naive people living with human immunodeficiency virus type 1 (HIV). Noninferiority of DTG to EFV400 was demonstrated at 48-week and sustained at 96 weeks. Here, we present results at 192-week. Methods: Previous trial participants were reconsented and followed up on their initial randomization arm (1:1 DTG/TDF/3TC:EFV400/TDF/3TC). Assessments included changes in viral suppression, biological parameters, and new serious adverse events (SAEs). Results: Among the participants enrolled in the trial, 81% (499/613) were analyzed at week 192: 84% (261/310) on DTG/TDF/3TC and 78% (238/303) on EFV400/TDF/3TC. HIV RNA suppression was maintained in 69% (214/310) on DTG/TDF/3TC-based and 62% (187/303) on EFV400/TDF/3TC-based regimens (difference, 7.3% [95% confidence interval, −.20 to 14.83]; P = .057). Five (DTG/TDF/3TC = 2; EFV400/TDF/3TC = 3) new viral failures (World Health Organization definition) without related resistance DTG mutations and 24 new SAEs were observed (DTG/TDF/3TC = 13; EFV400/TDF/3TC = 11). Mean weight gain was +9.4 kg on DTG/TDF/3TC and +5.9 kg on EFV400/TDF/3TC. The percentage of participants with obesity increased from 6.9% to 27.7% on DTG/TDF/3TC (P < .0001) and from 8.3% to 16.7% on EFV400/TDF/3TC (P = .0033). Conclusions: Four-year follow-up of people with HIV on DTG- and EFV400-based regimens showed long-term efficacy and safety of both ARTs, markedly among participants on DTG/TDF/3TC with high baseline viral load. However, unexpected substantial weight gain over time was prominent among participants on DTG/TDF/3TC, which should be closely monitored. Clinical Trials Registration. NCT02777229.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz–Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study
Author / Organization Mireille Mpoudi-Etame, Tamara Tovar Sanchez, Marwân-Al-Qays Bousmah, Pierrette Omgba Bassega, Justin Olinga, Eric Mimbe, Michel Foalem, Camille Chiep, Serge Edimo, Marie Varloteaux, Raphaël Pelloquin, Nadine Lamare, Sylvie Boyer, Martine Peeters, Jacques Reynes, Alexandra Calmy, Andrew Hill, Eric Delaporte, Charles Kouanfack, Ahidjo Ayouba, A Agholeng, Christelle Butel, B Granouillac, A Lacroix, Sandrine Leroy, L Serrano, C Kounfack, Nicole Vidal, P Fouda, R Mougnoutou, V Omgba, S Tchokonte Ngandé, B Ymele, L Donfack, A Kambi, C Epoupa Mpacko, M Fotso, R Moukoko, T Nké, A Akamba, S Lekelem, S Ngono, S Tongo Fotack, M Tanga, M Tsafack, A Bissek, L Ciaffi, S Lem, M Niba, N Camille, Eitel Mpoudi-Ngole, E Ebong, G Edoul Mbesse, M Tongo, P Huynh, Gwenaëlle Maradan, Marie Libérée Nishimwe, Bruno Spire, Gilles Peytavin, Mp Lê, Yazdan Yazdanpanah, A Diallo, I Fournier, A Montoyo, N Mercier, Ventizlava Petrov‐sanchez, J Jean-Rassat, Claire Rekacewicz, C Perez Casas
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2023
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-202069
Original Source Link Visit Source Page on hal.science »